References
- Abraham, M. J., van der Spoel, D., Lindahl, E., & Hess, B. (2018). GROMACS user manual version.
- Avula, S., Komsani, J., Koppireddi, S., Yadla, R., Kanugula, A., & Kotamraju, S. (2012). Synthesis and cytotoxicity of novel 6H-indolo [2, 3-b] quinoxaline derivatives. Medicinal Chemistry Research, 22(8), 3712–3718.
- Bartus, R. T., Dean, R. R., Beer, B., & Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science (New York, N.Y.), 217(4558), 408–414. https://doi.org/https://doi.org/10.1126/science.7046051
- Bixon, M., & Lifson, S. (1967). Potential functions and conformations in cycloalkanes. Tetrahedron, 23, 769–784.
- Bonda, D. J., Wang, X., Perry, G., Nunomura, A., Tabaton, M., Zhu, X., & Smith, M. A. (2010). Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology, 59(4–5), 290–294. https://doi.org/https://doi.org/10.1016/j.neuropharm.2010.04.005
- Brunhofer, G., Fallarero, A., Karlsson, D., Batista-Gonzalez, A., Shinde, P., Gopi Mohan, C., & Vuorela, P. (2012). Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: The case of chelerythrine. Bioorganic & Medicinal Chemistry, 20(22), 6669–6679. https://doi.org/https://doi.org/10.1016/j.bmc.2012.09.040
- Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008). Multi-target-directed ligands to combat neurodegenerative diseases. Journal of Medicinal Chemistry, 51(3), 347–372. https://doi.org/https://doi.org/10.1021/jm7009364
- Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018). Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biology, 14, 450–464. https://doi.org/https://doi.org/10.1016/j.redox.2017.10.014
- Cheung, J., Rudolph, M. J., Burshteyn, F., Cassidy, M. S., Gary, E. N., Love, J., Franklin, M. C., & Height, J. J. (2012). Structures of human acetylcholinesterase in complex with pharmacologically important ligands. Journal of Medicinal Chemistry, 55(22), 10282–10286. https://doi.org/https://doi.org/10.1021/jm300871x
- Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An N ⋅log( N ) method for Ewald sums in large systems. Journal of Chemical Physics, 98(12), 10089–10092. https://doi.org/https://doi.org/10.1063/1.464397
- Di, L., Kerns, E. H., Fan, K., McConnell, O. J., & Carter, G. T. (2003). High throughput artificial membrane permeability assay for blood-brain barrier. European Journal of Medicinal Chemistry, 38(3), 223–232.
- Di, L., Kerns, E. H., Bezar, I. F., Petusky, S. L., & Huang, Y. (2009). Comparison of blood–brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB. Journal of Pharmaceutical Sciences, 98, 1980–1991.
- Dighe, S. N., Deora, G. S., De la Mora, E., Nachon, F., Chan, S., Parat, M. O., Brazzolotto, X., & Ross, B. P. (2016). Discovery and structure–activity relationships of a highly selective butyrylcholinesterase inhibitor by structure-based virtual screening. Journal of Medicinal Chemistry, 59, 7683–7689.
- Glide. (2018). Glide. Schrodinger, LLC.
- Greenough, M. A., Camakaris, J., & Bush, A. I. (2013). Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochemistry International, 62(5), 540–555. [Database] https://doi.org/https://doi.org/10.1016/j.neuint.2012.08.014
- Greig, N. H., Lahiri, D. K., & Sambamurti, K. (2002). Butyrylcholinesterase: An important new target in Alzheimer's Disease therapy. International Psychogeriatrics, 14(S1), 77–91. https://doi.org/https://doi.org/10.1017/S1041610203008676
- Greig, N. H., Utsuki, T., Ingram, D. K., Wang, Y., Pepeu, G., Scali, C., Yu, Q.-S., Mamczarz, J., Holloway, H. W., & Giordano, T. (2005). Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer -amyloid peptide in rodent. Proceedings of the National Academy of Sciences, 102(47), 17213–17218.
- Gu, Z., Li, Y., Ma, S., Li, S., Zhou, G., Ding, S., Zhang, J., Wang, S., & Zhou, C. (2017). Synthesis, cytotoxic evaluation and DNA binding study of 9-fluoro-6H-indolo[2,3-b]quinoxaline derivatives. RSC Advances, 7(66), 41869–41879. https://doi.org/https://doi.org/10.1039/C7RA08138C
- Hardy, J. A., & Higgins, G. A. (1992). Alzheimer's disease: The amyloid cascade hypothesis. Science, 256(5054), 184–186.
- Hartmann, J., Kiewert, C., Duysen, E. G., Lockridge, O., Greig, N. H., & Klein, J. (2007). Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. Journal of Neurochemistry, 100(5), 1421–1429. https://doi.org/https://doi.org/10.1111/j.1471-4159.2006.04347.x
- Huang, J., Rauscher, S., Nawrocki, G., Ran, T., Feig, M., de Groot, B. L., Grubmüller, H., & MacKerell Jr, A. D. (2017). CHARMM36m: An improved force field for folded and intrinsically disordered proteins. Nature Methods, 14(1), 71–73. https://doi.org/https://doi.org/10.1038/nmeth.4067
- Kanhed, A. M., Sinha, A., Machhi, J., Tripathi, A., Parikh, Z. S., Pillai, P. P., Giridhar, R., & Yadav, M. R. (2015). Discovery of isoalloxazine derivatives as a new class of potential anti-Alzheimer agents and their synthesis. Bioorganic Chemistry, 61, 7–12.
- Kelder, J., Grootenhuis, P. D., Bayada, D. M., Delbressine, L. P., & Ploemen, J.-P. (1999). Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharmaceutical Research, 16(10), 1514–1519. https://doi.org/https://doi.org/10.1023/A:1015040217741
- Lane, C. A., Hardy, J., & Schott, J. M. (2018). Alzheimer's disease. European Journal of Neurology, 25(1), 59–70. https://doi.org/https://doi.org/10.1111/ene.13439
- Lane, R. M., Potkin, S. G., & Enz, A. (2006). Targeting acetylcholinesterase and butyrylcholinesterase in dementia. The International Journal of Neuropsychopharmacology, 9, 101–124.
- Li, S.-Y., Wang, X.-B., Xie, S.-S., Jiang, N., Wang, K. D., Yao, H.-Q., Sun, H.-B., & Kong, L.-Y. (2013). Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 69, 632–646. https://doi.org/https://doi.org/10.1016/j.ejmech.2013.09.024
- Ligprep. (2018). Ligprep. Schrodinger, LLC.
- Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23(1–3), 3–25. [Database] https://doi.org/https://doi.org/10.1016/S0169-409X(96)00423-1
- Lobo, V., Patil, A., Phatak, A., & Chandra, N. (2010). Free radicals, antioxidants and functional foods: Impact on human health. Pharmacognosy Reviews, 4(8), 118–126. https://doi.org/https://doi.org/10.4103/0973-7847.70902
- López-Iglesias, B., Pérez, C., Morales-García, J. A., Alonso-Gil, S., Pérez-Castillo, A., Romero, A., López, M. G., Villarroya, M., Conde, S., & Rodríguez-Franco, M. I. (2014). New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease. Journal of Medicinal Chemistry, 57(9), 3773–3785. https://doi.org/https://doi.org/10.1021/jm5000613
- Maccioni, R. B., Farías, G., Morales, I., & Navarrete, L. (2010). The revitalized tau hypothesis on Alzheimer's disease. Archives of Medical Research, 41(3), 226–231. https://doi.org/https://doi.org/10.1016/j.arcmed.2010.03.007
- Mark, P., & Nilsson, L. (2001). Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. Journal of Physical Chemistry A, 43, 9954–9960.
- McEneny-King, A., Osman, W., Edginton, A. N., & Rao, P. P. N. (2017). Cytochrome P450 binding studies of novel tacrine derivatives: Predicting the risk of hepatotoxicity. Bioorganic & Medicinal Chemistry Letters, 27(11), 2443–2449. https://doi.org/https://doi.org/10.1016/j.bmcl.2017.04.006
- Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791.
- O'Brien, R. J., & Wong, P. C. (2011). Amyloid precursor protein processing and Alzheimer's disease. Annual Review of Neuroscience, 34, 185–204.
- Pachon-Angona, I., Refouvelet, B., Andrys, R., Martin, H., Luzet, V., Iriepa, I., Moraleda, I., Diez-Iriepa, D., Oset-Gasque, M. J., Marco-Contelles, J., Musilek, K., & Ismaili, L. (2019). Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapy. Journal of Enzyme Inhibition and Medicinal Chemistry, 34, 479–489.
- Pajouhesh, H., & Lenz, G. R. (2005). Medicinal chemical properties of successful central nervous system drugs. NeuroRx: The Journal of the American Society for Experimental Neurotherapeutics, 2(4), 541–553. https://doi.org/https://doi.org/10.1602/neurorx.2.4.541
- Patel, D. V., Patel, N. R., Kanhed, A. M., Patel, S. P., Sinha, A., Kansara, D. D., Mecwan, A. R., Patel, S. B., Upadhyay, P. N., Patel, K. B., Shah, D. B., Prajapati, N. K., Murumkar, P. R., Patel, K. V., & Yadav, M. R. (2019). Novel multitarget directed triazinoindole derivatives as anti-alzheimer agents. ACS Chemical Neuroscience, 10, 3635–3661.
- Patel, D. V., Patel, N. R., Kanhed, A. M., Teli, D. M., Patel, K. B., Joshi, P. D., Patel, S. P., Gandhi, P. M., Chaudhary, B. N., Prajapati, N. K., Patel, K. V., & Yadav, M. R. (2020). Novel carbazole-stilbene hybrids as multifunctional anti-Alzheimer agents. Bioorganic Chemistry, 101, 103977.
- Patterson, C. (2018). Alzheimer’s Disease International. ADI.
- Pohanka, M. (2011). Cholinesterases, a target of pharmacology and toxicology. Biomedical Papers of the Medical Faculty of Palacky University in Olomouc, 155.
- Protein Data Bank. (2019). Retrieved August 9, 2019, from www.rcsb.org/pdb/home/home.do.
- QikProp. (2018). QikProp. Schrödinger, LLC.
- Ramos, E., Palomino-Antolin, A., Bartolini, M., Iriepa, I., Moraleda, I., Diez-Iriepa, D., Samadi, A., Cortina, C. V., Chioua, M., Egea, J., Romero, A., & Marco-Contelles, J. (2019). QuinoxalineTacrine QT78, a Cholinesterase inhibitor as a potential ligand for Alzheimer’s Disease therapy. Molecules (Basel, Switzerland), 24(8), 1503.
- Rodríguez-Franco, M. I., Fernández-Bachiller, M. I., Pérez, C., Hernández-Ledesma, B., & Bartolomé, B. (2006). Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. Journal of Medicinal Chemistry, 49(2), 459–462. https://doi.org/https://doi.org/10.1021/jm050746d
- Sanner, M. F. (1999). Python: a programming language for software integration and development. Journal of Molecular Graphics and Modelling, 17, 57–61.
- Scheltens, P., Blennow, K., Breteler, M. M., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016). Alzheimer's disease. Lancet (London, England), 388(10043), 505–517.
- Selkoe, D. J. (2003). Folding proteins in fatal ways. Nature, 426, 900.
- Shidore, M., Machhi, J., Shingala, K., Murumkar, P., Sharma, M. K., Agrawal, N., Tripathi, A., Parikh, Z., Pillai, P., & Yadav, M. R. (2016). Benzylpiperidine-linked diarylthiazoles as potential anti-Alzheimer's agents: Synthesis and biological evaluation. Journal of Medicinal Chemistry, 59, 5823–5846.
- Sinha, A., Tamboli, R. S., Seth, B., Kanhed, A. M., Tiwari, S. K., Agarwal, S., Nair, S., Giridhar, R., Chaturvedi, R. K., & Yadav, M. R. (2015). Neuroprotective role of novel triazine derivatives by activating Wnt/β catenin signaling pathway in rodent models of Alzheimer's Disease. Molecular Neurobiology, 52(1), 638–652.
- Talesa, V. N. (2001). Acetylcholinesterase in Alzheimer's disease. Mechanisms of Ageing and Development, 122(16), 1961–1969. https://doi.org/https://doi.org/10.1016/s0047-6374(01)00309-8
- Uttara, B., Singh, A. V., Zamboni, P., & Mahajan, R. (2009). Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options. Current Neuropharmacology, 7(1), 65–74. [Database] https://doi.org/https://doi.org/10.2174/157015909787602823
- Vanommeslaeghe, K., Hatcher, E., Acharya, C., Kundu, S., Zhong, S., Shim, J., Darian, E., Guvench, O., Lopes, P., Vorobyov, I., & MacKerell Jr, A. D. (2010). CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields. Journal of Computational Chemistry, 31, 671–690.
- Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry, 45(12), 2615–2623. https://doi.org/https://doi.org/10.1021/jm020017n
- Yanovsky, I., Finkin-Groner, E., Zaikin, A., Lerman, L., Shalom, H., Zeeli, S., Weill, T., Ginsburg, I., Nudelman, A., & Weinstock, M. (2012). Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease. Journal of Medicinal Chemistry, 55(23), 10700–10715. https://doi.org/https://doi.org/10.1021/jm301411g
- Yu, W., He, X., Vanommeslaeghe, K., & MacKerell Jr, A. D. (2012). Extension of the CHARMM general force field to sulfonyl‐containing compounds and its utility in biomolecular simulations. Journal of Computational Chemistry, 33, 2451–2468.
- Zhao, Y., & Zhao, B. (2013). Oxidative stress and the pathogenesis of Alzheimer's disease. Oxidative Medicine and Cellular Longevity, 2013, 1–10.